The committee will discuss saxagliptin tablets, by Bristol-Myers Squibb, for the treatment of hyperglycemia in adults with type 2 diabetes mellitus - International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use - Document - PDFSEARCH.IO

First Page	Meta Content
	The committee will discuss saxagliptin tablets, by Bristol-Myers Squibb, for the treatment of hyperglycemia in adults with type 2 diabetes mellitus Add to Reading List Open Document File Size: 45,67 KB Share Result on Facebook Company Other Initiatives FDA Monograph Modernization Task Group / / Facility FDA White Oak Campus / White Oak Conference Center / / Organization Research Advisory Committee for Pharmaceutical Science / FDA’s office of Pharmaceutical Science / FDA / FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation / Research Advisory Committee for Pharmaceutical Science and Clinical Pharmacology / European Union / / Person Yvette Waples / / Position Federal Officer / TBA Acting Chair of Committee / / SocialTag Drug safety Medicine Quality Quality by Design Food and Drug Administration United States Pharmacopeia Over-the-counter drug International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Monograph Pharmaceuticals policy

The committee will discuss saxagliptin tablets, by Bristol-Myers Squibb, for the treatment of hyperglycemia in adults with type 2 diabetes mellitusAdd to Reading List